ENTL Entelos Regs

        Entelos, Inc. (LSE: ENTL) today is updating the market in advance of its year-end period ending 31 December 2008.
    The current economic crisis has impacted almost every industry including our customer segment. Many of our
pharmaceutical customers have recently announced delays in some of their internal drug development programs. As a
result, the Company expects its fourth quarter revenues, and therefore full year revenues, to be below expectations. The
Company has made progress towards cash flow breakeven as cash receipts will be higher in the second half of 2008
compared to the first half of the year thus reducing the Company's burn rate.
    The Company plans to report its full-year financial results in March 2009.
     Enquiries 
 Entelos, Inc.                                       
 Alan Blazei, Chief Financial Officer                  Tel: +1 650 572 5400
 Jill Fujisaki, Vice President, Investor Relations
                                                                                
 KBC Peel Hunt, Ltd (Nominated Advisor and Broker)
 Capel Irwin/David Anderson                            Tel: +44 (0) 20 4718 8900
                                                                                
 Buchanan Communications
 Lisa Baderoon/Mary-Jane Johnson                       Tel: +44 (0)20 7466 5000
     About Entelos, Inc. 
    Entelos, Inc. ( www.entelos.com) is a US-based life sciences company applying next-generation predictive
technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its
proprietary in silico disease models, "virtual human" technology, and toxicology reference systems to develop safer and
more effective drugs, improve the quality of health-related consumer products, and deliver on the promise of
personalized medicine. Entelos provides customized products, technology and research services to global pharmaceutical,
health-care, and consumer products companies in safety testing, arthritis, cardiovascular diseases, asthma, obesity,
diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care products.
    
    

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From May 2024 to Jun 2024

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jun 2023 to Jun 2024